Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Payables (2020 - 2025)

Rapid Micro Biosystems' Payables history spans 6 years, with the latest figure at $4.1 million for Q4 2025.

  • On a quarterly basis, Payables rose 63.27% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 63.27% increase, with the full-year FY2025 number at $4.1 million, up 63.27% from a year prior.
  • Payables hit $4.1 million in Q4 2025 for Rapid Micro Biosystems, up from $3.6 million in the prior quarter.
  • Over the last five years, Payables for RPID hit a ceiling of $5.4 million in Q4 2022 and a floor of $1.2 million in Q1 2024.
  • Historically, Payables has averaged $2.8 million across 5 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Payables: crashed 63.75% in 2023 and later skyrocketed 126.37% in 2025.
  • Tracing RPID's Payables over 5 years: stood at $3.9 million in 2021, then surged by 37.63% to $5.4 million in 2022, then plummeted by 63.65% to $2.0 million in 2023, then rose by 28.48% to $2.5 million in 2024, then soared by 63.27% to $4.1 million in 2025.
  • Business Quant data shows Payables for RPID at $4.1 million in Q4 2025, $3.6 million in Q3 2025, and $3.3 million in Q2 2025.